Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CD40_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CD40_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CD40_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:01405467 | Thyroid | PTC | defense response to symbiont | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
GO:00434918 | Thyroid | PTC | protein kinase B signaling | 88/5968 | 211/18723 | 1.59e-03 | 8.81e-03 | 88 |
GO:004354219 | Thyroid | PTC | endothelial cell migration | 112/5968 | 279/18723 | 2.03e-03 | 1.09e-02 | 112 |
GO:00434057 | Thyroid | PTC | regulation of MAP kinase activity | 75/5968 | 177/18723 | 2.04e-03 | 1.09e-02 | 75 |
GO:004354714 | Thyroid | PTC | positive regulation of GTPase activity | 103/5968 | 255/18723 | 2.38e-03 | 1.25e-02 | 103 |
GO:004576612 | Thyroid | PTC | positive regulation of angiogenesis | 75/5968 | 181/18723 | 4.09e-03 | 1.95e-02 | 75 |
GO:190401812 | Thyroid | PTC | positive regulation of vasculature development | 75/5968 | 181/18723 | 4.09e-03 | 1.95e-02 | 75 |
GO:190401913 | Thyroid | PTC | epithelial cell apoptotic process | 52/5968 | 121/18723 | 6.56e-03 | 2.86e-02 | 52 |
GO:00705558 | Thyroid | PTC | response to interleukin-1 | 60/5968 | 143/18723 | 6.93e-03 | 2.98e-02 | 60 |
GO:000758417 | Thyroid | PTC | response to nutrient | 71/5968 | 174/18723 | 7.82e-03 | 3.31e-02 | 71 |
GO:003434110 | Thyroid | PTC | response to interferon-gamma | 59/5968 | 141/18723 | 7.88e-03 | 3.33e-02 | 59 |
GO:00022004 | Thyroid | PTC | somatic diversification of immune receptors | 35/5968 | 77/18723 | 8.56e-03 | 3.59e-02 | 35 |
GO:00434063 | Thyroid | PTC | positive regulation of MAP kinase activity | 48/5968 | 112/18723 | 9.30e-03 | 3.83e-02 | 48 |
GO:00164453 | Thyroid | PTC | somatic diversification of immunoglobulins | 31/5968 | 67/18723 | 9.51e-03 | 3.91e-02 | 31 |
GO:00182126 | Thyroid | PTC | peptidyl-tyrosine modification | 142/5968 | 378/18723 | 1.02e-02 | 4.14e-02 | 142 |
GO:001059416 | Thyroid | PTC | regulation of endothelial cell migration | 91/5968 | 232/18723 | 1.03e-02 | 4.18e-02 | 91 |
GO:00164473 | Thyroid | PTC | somatic recombination of immunoglobulin gene segments | 27/5968 | 57/18723 | 1.04e-02 | 4.18e-02 | 27 |
GO:000238113 | Thyroid | PTC | immunoglobulin production involved in immunoglobulin-mediated immune response | 32/5968 | 70/18723 | 1.05e-02 | 4.23e-02 | 32 |
GO:004206034 | Thyroid | ATC | wound healing | 210/6293 | 422/18723 | 3.33e-12 | 1.37e-10 | 210 |
GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0514525 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0541630 | Esophagus | ESCC | Viral myocarditis | 41/4205 | 60/8465 | 2.59e-03 | 7.05e-03 | 3.61e-03 | 41 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa05145111 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa05416114 | Esophagus | ESCC | Viral myocarditis | 41/4205 | 60/8465 | 2.59e-03 | 7.05e-03 | 3.61e-03 | 41 |
hsa0516928 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa0541730 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
hsa0514520 | Oral cavity | OSCC | Toxoplasmosis | 75/3704 | 112/8465 | 5.28e-07 | 3.16e-06 | 1.61e-06 | 75 |
hsa040644 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0541629 | Oral cavity | OSCC | Viral myocarditis | 39/3704 | 60/8465 | 7.13e-04 | 2.09e-03 | 1.07e-03 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD40 | SNV | Missense_Mutation | | c.316G>A | p.Glu106Lys | p.E106K | P25942 | protein_coding | tolerated(1) | benign(0) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
CD40 | SNV | Missense_Mutation | novel | c.808N>T | p.Arg270Cys | p.R270C | P25942 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
CD40 | insertion | In_Frame_Ins | novel | c.241_242insGTGTGGGAGCTCCACGTTCACAGGATGGTGTCTTGC | p.Lys81delinsSerValGlyAlaProArgSerGlnAspGlyValLeuGln | p.K81delinsSVGAPRSQDGVLQ | P25942 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CD40 | insertion | In_Frame_Ins | novel | c.643_644insAAGGGGAGGGGAGGCAGTTTGGGGGTGTGGTATCACAGC | p.Ile215delinsLysGlyGluGlyArgGlnPheGlyGlyValValSerGlnLeu | p.I215delinsKGEGRQFGGVVSQL | P25942 | protein_coding | | | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
CD40 | SNV | Missense_Mutation | | c.570N>A | p.Asp190Glu | p.D190E | P25942 | protein_coding | tolerated(0.26) | benign(0.01) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CD40 | SNV | Missense_Mutation | | c.131N>T | p.Gly44Val | p.G44V | P25942 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-5348-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CD40 | SNV | Missense_Mutation | | c.8G>A | p.Arg3His | p.R3H | P25942 | protein_coding | tolerated(0.06) | possibly_damaging(0.642) | TCGA-G4-6303-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD |
CD40 | SNV | Missense_Mutation | | c.475G>A | p.Glu159Lys | p.E159K | P25942 | protein_coding | deleterious(0.02) | possibly_damaging(0.866) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CD40 | SNV | Missense_Mutation | novel | c.505A>C | p.Thr169Pro | p.T169P | P25942 | protein_coding | tolerated(0.15) | benign(0.184) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
CD40 | SNV | Missense_Mutation | novel | c.662A>C | p.Lys221Thr | p.K221T | P25942 | protein_coding | tolerated(0.07) | benign(0.15) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | LUCATUMUMAB | LUCATUMUMAB | |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | APX005M | APX-005M | |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | BI 655064 | | |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | ABBV-323 | RAVAGALIMAB | |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | RECOMBINANT HUMAN IL-2 | | 10383947 |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | KINASE INHIBITOR | | 17307797 |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | partial agonist | CHEMBL2108144 | TENELIXIMAB | |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | CFZ533 | ISCALIMAB | |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | SGN-14 | | 10866315 |
958 | CD40 | CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | HYDROQUINONE | HYDROQUINONE | 17118622 |